Special Issue "The Role of Autophagy in Cancer Progression and Drug Resistance"
A special issue of Cancers (ISSN 2072-6694).
Deadline for manuscript submissions: 30 September 2019
Dr. Steffan T. Nawrocki
Autophagy is an evolutionarily conserved lysosome-mediated protein degradation process that functions to turnover organelles and proteins with long half-lives. This role of autophagy suppresses tumor formation via the elimination of defective pre-malignant cells and maintains bioenergetic homeostasis under stress conditions including hypoxia and nutrient deprivation. However, autophagy may also promote cancer progression and drug resistance in established diseases via the generation of alternative sources of energy through nutrient recycling. Despite having diverse mechanisms of action, many frontline anticancer agents ultimately shut down conventional metabolic pathways because of the cellular stress that they impose and, thus, stimulate autophagy. Importantly, pharmacological or genetic inhibition of autophagy significantly enhances the anticancer activity of many different forms of cancer therapeutics. On the basis of these collective findings, it appears that inhibition of autophagy is a promising novel approach with broad applications in cancer therapy. We welcome articles focused on autophagy and its roles in cancer progression and drug resistance.
Dr. Steffan T. Nawrocki
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- protein degradation
- drug resistance
- cell survival
- cell metabolism
- combination therapy